Acurx Pharmaceuticals, Inc. ACXP

Company Overview

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule antibiotics for difficult-to-treat bacterial infections. The company primarily operates within the anti-infective and pharmaceutical development industries, with a strategic emphasis on therapies that address antimicrobial resistance and reduce recurrence rates associated with serious bacterial diseases. Its lead development programs target infections caused by Gram-positive bacteria, particularly Clostridioides difficile infection (CDI), an area with significant unmet medical need in hospital and long-term care settings.

The company’s principal revenue drivers remain tied to research and development activities and capital financing, as Acurx has not yet commercialized a product. Its lead product candidate, ibezapolstat, is being developed as a novel antibiotic treatment for CDI and is designed to selectively inhibit bacterial DNA polymerase IIIC, a mechanism differentiated from many currently marketed antibiotics. Acurx evolved from a broader biotechnology platform into a more specialized anti-infectives developer after emphasizing precision-targeted antibiotic therapies intended to preserve the gut microbiome while reducing recurrence and resistance risks. Public disclosures, including SEC filings, indicate the company has concentrated its resources on advancing late-stage clinical development and intellectual property protection surrounding its lead assets.